Introduction: The upregulation of programmed death ligand 1 (PD-L1) is found in many cancers and contributes to evasion of the host's immune defense. In malignant pleural mesothelioma (MPM), PD-L1 expression is associated with the nonepithelioid histological subtype and poor prognosis, but the pathways involved in control of PD-L1 expression in MPM are poorly understood. To address one possible means of PD-L1 regulation we investigated the relationship between dysregulated microRNA levels and PD-L1 expression.
Methods: PD-L1 expression was analyzed by immunohistochemistry in tissue microarrays prepared from samples from patients undergoing an operation (pleurectomy with or without decortication). MicroRNA expression was analyzed by reverse-transcriptase quantitative polymerase chain reaction. Regulation of PD-L1 expression in cell lines was assessed after transfection with microRNA mimics and small interfering RNAs. Interaction between microRNAs and PD-L1 was analyzed by using argonaute-2 immunoprecipitation and a luciferase reporter assay.
Results: In a series of 72 patients with MPM, 18 (25%) had positive PD-L1 staining, and this was more common in patients with the nonepithelioid subtype (p ¼ 0.01). PD-L1 expression was associated with poor survival (median overall survival 4.0 versus 9.2 months with positive versus negative PD-L1 expression [p < 0.001]), and in multivariate analyses, PD-L1 expression remained a significant adverse prognostic indicator (hazard ratio ¼ 2.2, 95% confidence interval: 1.2-4.1, p < 0.01). In the same patient series, PD-L1 expression was also associated with downregulation of microRNAs previously shown to have tumor suppressor activity in MPM. The median microRNA expression levels of miR-15b, miR-16, miR-193a-3p, miR-195, and miR-200c were significantly lower in the PD-L1-positive samples. Transfecting MPM cell lines with mimics corresponding to miR-15a and miR-16, both of which are predicted to target PD-L1, led to downregulation of PD-L1 mRNA and protein. In addition, miR-193a-3p, with an alternative G-U-containing target site, also caused PD-L1 downregulation.
Introduction
Malignant pleural mesothelioma (MPM) is an aggressive, asbestos-induced cancer affecting the pleural surface. Patients with this disease typically have a poor prognosis, with a median survival of 12 months, 1, 2 On an individual basis, prognosis can be quite variable, with up to 8% of male and 18% of female patients reaching a 5-year survival. 3 Chemotherapy with platinum and pemetrexed/raltitrexed is the only systemic treatment providing a survival advantage and a quality of life benefit in clinical trials. 1, 4 Although this combination was recently improved by the addition of bevacizumab, 5 response rates continue to be modest (at best 40% 1 ), and better prognostic biomarkers and more effective treatment approaches are urgently needed.
The development of MPM is closely associated with chronic inflammation. 6, 7 At the same time, there is a rapidly increasing body of evidence showing that the immune system is able to mount a response to MPM. 8 Programmed death-ligand 1 (PD-L1) is a negative costimulatory protein encoded by the CD274 molecule gene (CD274) gene, which is expressed on cells of the macrophage lineage, in which it is able to inhibit T-lymphocyte activation by binding to the programmed cell death 1 (PD-1) receptor. 9 Abnormal cell-surface expression of PD-L1 in tumors has been shown to limit T-cell antitumor activity (T-cell anergy), affording tumors protection against killer T-cell elimination. 10, 11 Recently, a new class of drugs that block the PD-1/ PD-L1 axis has shown ability to activate the immune system and induce objective responses of significant duration in patients with metastatic melanoma and lung cancer. [12] [13] [14] There are now also preliminary data suggesting that this approach of checkpoint inhibition is able to induce meaningful responses in patients with MPM. 15 Multiple pathways appear to contribute to the control of PD-L1 in cancer cells. For example, interferon (IFN) gamma (IFN-g) and Toll-like receptor 4 signaling increase PD-L1 levels in multiple myeloma 16 and bladder cancer. 17 In a lung cancer cell line, both constitutive and IFN-g-stimulated signaling is affected by IFN regulatory factor I (IRF1) binding to the promoter of the CD274 gene. 18 In melanoma cells, IFN-g-inducible expression of PD-L1 is dependent on nuclear factor kB. 19 Moreover, in melanoma cells resistant to BRAF inhibition, activation of mitogenactivated protein kinase led to signal transducer and activator of transcription 3-mediated PD-L1 upregulation, 20 whereas signal transducer and activator of transcription 1 increased PD-L1 levels in endometrial cancer. 21 In lung cancer, cells positive for the echinoderm microtubule associated protein like 4 gene (EML4)/ALK receptor tyrosine kinase gene (ALK) fusion 22 or mutant EGFR 23 had higher PD-L1 expression, and this could be prevented by inhibitors of anaplastic lymphoma kinase, MEK/ERK, or phosphoinositide 3-kinase/AKT signaling 22 or EGFR tyrosine kinase inhibitors. 23 In MPM, PD-L1 expression appeared to be inversely related to the commonly down-regulated tumor suppressor candidate 2 24 and IFN-g was able to stimulate IRF1 expression in MPM cell lines. 25 In addition to alterations in transcriptional control of PD-L1 expression, there are other molecular events responsible for differences in PD-L1 protein levels. Although PD-L1 mRNA expression is readily detectable in many cell types, the protein is frequently undetectable, 9 suggesting that posttranscriptional regulation by microRNAs could be involved. In gastric cancer, a common G>C mutation in the 3 prime untranslatable region (3 0 UTR) of PD-L1 leads to a change in the binding site for miR-570, and this is associated with an overexpression of PD-L1 protein in tumors. 26 More recently, members of the miR-200 27 and miR-34 28 families were shown to be negatively correlated with PD-L1 expression in lung cancer, and to regulate PD-L1 expression in lung cancer cells in vitro and in vivo.
Previous studies have shown that PD-L1 is upregulated in the tumor cells of a subset of patients with MPM, 29, 30 but the mechanisms responsible have yet to be investigated. In this study we have analyzed PD-L1 expression in tumor samples from a series of patients with MPM and related it to the expression of microRNAs predicted to posttranscriptionally regulate the PD-L1 mRNA. In addition to confirming the negative prognostic impact of PD-L1 expression, our studies show that tumor suppressor microRNA levels are lower in tumors with high PD-L1 expression, and that they can regulate PD-L1 expression in vitro.
Materials and Methods

Patients
A total of 74 consecutive patients with MPM undergoing pleurectomy with or without decortication at Royal Prince Alfred Hospital in Sydney between 1992 and 2007 were examined, 31 and those with assessable tumor sample cores (n ¼ 72) were included in this study. Diagnosis and subtyping (epithelioid, sarcomatoid, and biphasic) were done in accordance with the WHO classification 32 and sarcomatoid and biphasic histological subtypes were grouped as nonepithelioid. 
Immunohistochemistry
The tissue microarray (TMA) used in this study and its method of construction were described previously. 31, 33 From this TMA, 3-mm tissue sections were cut onto Superfrost Ultra Plus glass slides and stored at 4 C until immunohistochemistry was performed (<2 weeks). Immunohistochemistry was performed on a Bond III Autostainer/PTLink using the Bond Polymer Refine Detection Kit (Leica Biosystems, Nussloch, Germany), with high-pH target retrieval buffer (Leica Biosystems), as per manufacturer's instructions. The primary antibody against PD-L1 (E1L3N XP Rabbit Monoclonal Antibody [Cell Signaling Technology, Danvers, MA) was incubated for 30 minutes at room temperature at a 1:75 dilution. Membranous labeling of PD-L1 in tumor cells was considered positive staining. For quantitative evaluation, the percentage of positive tumor cells in the cores of each patient (0%-100%), irrespective of intensity, was assessed. The assessor was blinded to the other clinical details, including survival. An average score was derived by averaging the scores from assessable cores for each patient. Cases of PD-L1 expression of 5% or more were considered positive, as per the previous MPM study. 34 For assessment of PD-L1 staining in cell lines, transfected cells were pelleted and embedded in paraffin, after which 8-mm sections were cut and analyzed as described earlier.
Assessment of MicroRNA Expression in Tumor Samples
MicroRNAs predicted to bind to the 3 0 UTR of PD-L1 mRNA were identified by using TargetScan (release 6.2) and microRNA.org online prediction tools. Levels of candidate microRNAs were assessed by reversetranscriptase quantitative polymerase chain reaction (RT-qPCR) in all samples that had been assessed for PD-L1 protein expression (PD-L1-positive [n ¼13] and PD-L1-negative [n ¼ 50]) and for which RNA was available. The RNA used for assessment of microRNAs was isolated as part of a previous study from laser capture-microdissected tumor tissue from whole sections of the same tumor blocks used for TMA construction. 35 MicroRNA-specific RT-qPCR measurements were performed as described previously. 36, 37 In brief, 100-ng sections of total RNA were reverse-transcribed using the MicroRNA Reverse Transcription Kit (Thermo Fisher Scientific [Waltham, MA]) and microRNA-specific reverse transcription primers (Thermo Fisher Scientific [assay identifiers in Supplementary Table 1 ]) in a total reaction volume of 10 mL. The resulting complementary DNA (cDNA) was diluted with 57.8 mL of nuclease-free water, and 2.25 mL of diluted cDNA was subjected to qPCR reactions using KAPA FAST Probe Mastermix (Kapa Biosystems, Wilmington, MA) and microRNA-specific TaqMan probes (assay identifiers in Supplementary  Table 1 ) with a final reaction volume of 10 mL. qPCR reactions were carried out in duplicate, set up manually, and run on the ViiA7 Real Time System with 20 seconds of initial denaturing at 95 C followed by 40 cycles of 1 second at 95 C and 20 seconds of amplification at 60 C. Small nucleolar RNA RNU6B was used as an endogenous control, and relative microRNA expression was calculated by the modified 2 -DDCq method as previously described. 35 
Cell Lines
The MPM cell lines MSTO-H211 and H28 and the immortalized mesothelial cell line MeT-5A were purchased from the American Type Culture Collection (Manassas, VA) and grown in Roswell Park Memorial Institute medium supplemented with 10% fetal bovine serum. The VMC23 cell line, which was described previously, 38 was a kind gift from Michael Grusch (Vienna Medical Centre, Vienna, Austria). Cell lines were tested periodically for mycoplasma contamination by using the Mycoplasma Detection Kit (Life Technologies). Short tandem repeat profiling using the Promega GenePrint 10 system (Promega, Madison, WI) was carried out routinely (once per cell line per year) at the Australian Genome Research Facility (Melbourne, Australia).
MicroRNA Mimic and siRNA Transfection and In Vitro mRNA Analysis
MicroRNA mimics were designed to correspond to the mature microRNA sequence for miR-15a, miR-15b, miR-16, and miR-193a-3p as listed in miRBase and were purchased from GenePharma (Shanghai, China). The locked nucleic acid-containing miR-16 inhibitor and inhibitor control were purchased from Exiqon (Vedbaek, Denmark), and the miR-15b inhibitor was kindly provided by Jing Zhao (The Kolling Institute, Sydney, Australia). IRF1-specific small interfering RNAs (siRNAs) were designed by using the Invitrogen RNAi designer (Invitrogen, Carlsbad, CA); these and a previously described negative control siRNA 39 consisting of a sequence with no homology to human genes were purchased from GenePharma (Shanghai, People's Republic of China), which also provided a validated microRNA mimic control. Sequences of the microRNA mimics, siRNAs, and controls are provided in Supplementary  Table 1 . Where indicated, transfected cells were treated with IFN-g (kindly provided by Dr. Philip Fromm, ANZAC Research Institute, Sydney, Australia).
MPM cell lines (MSTO, H28, and VMC23) and the mesothelial line MeT-5A were plated in six-well plates (1.5 Â 10 5 cells per well); as indicated, they were reverse-transfected with microRNA mimics, microRNA inhibitors, siRNAs, or controls using Lipofectamine RNAiMAX (Thermo Fisher Scientific) as described previously. 37, 40 RNA was isolated from six-well plates 48 hours after transfection by using TRIzol (Fisher Thermo Scientific) as per the manufacturer's instructions. RNA quantification was carried out using a Nanophotometer (Implen, Munich, Germany) with readings at 260 and 280 nm; RNA was stored at -80 C for use within 1 week.
The Superscript III Reverse Transcriptase Kit (Thermo Fisher Scientific) was used to reverse-transcribe 500 ng of total RNA. The resultant cDNA was amplified with gene-specific primers (see Supplementary Table 1 ) and reference gene 18S by using 2x SYBR Green MasterMix (Thermo Fisher Scientific). Relative expression was calculated with the 2 -DDCq method. 41 
Protein Isolation and Western Immunoblotting
Cells were transfected with microRNA mimics or controls, and 72 hours later, protein was isolated using radioimmunoprecipitation assay buffer and quantified using a bicinchoninic protein assay (Thermo Fisher Scientific). PD-L1 protein expression was analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis followed by Western immunoblotting using the same PD-L1 specific antibody described earlier and an horeseradish peroxidase-conjugated anti-rabbit secondary (Abcam, Cambridge, United Kingdom). After the membrane was stripped, levels of b-actin were measured as a control by using a mouse anti-b-actin antibody (Sigma, St. Louis, MO) and a rabbit anti-mouse secondary antibody (Abcam). Imaging was carried out with a Gel Logic 2200 Imaging System (Kodak, Rochester, NY) under nonsaturating conditions.
AGO2 Immunoprecipitation
Cells were transfected with miR-15a, miR-16, miR193a-3p, or control mimics, and 48 hours later, cells were lysed and argonaute-2 (AGO2) protein was immunoprecipitated as previously described. 42, 43 Total RNA was isolated using TRIzol reagent, followed by RT-PCR with primers specific for CD274 mRNA. PCR products were run on 2% agarose gel and visualized with ethidium bromide. Imaging was carried out using a Gel Logic 2200 Imaging System (Kodak) under nonsaturating conditions.
Luciferase Reporter Assays
A 364-base pair fragment of the PD-L1 3 0 UTR-containing binding sites for miR-15a/15b/16 and miR-193a-3p (corresponding to nucleotides 1252-1615 in the RefSeq entry for CD274) was cloned from total RNA isolated from MSTO cells. RNA (500 ng) was reverse-transcribed using the Promega MMLV RT kit, and 40 ng cDNA was amplified using AmpliTaq Gold 360 (Promega) with the forward and reverse primers listed in Supplementary Table 1 . The PCR amplicon was cloned into the TOPO TA vector (Life Technologies, Carlsbad, CA) and sequence was confirmed by Sanger sequencing (Ramaciotti Centre, University of New South Wales, Sydney, Australia), before subcloning into the pSiCheck2 plasmid (Promega). The resultant reporter construct (1 mg), plus microRNA mimics or controls, was used to transfect 500,000 cells in six-well plates. After 48 hours, a dual luciferase assay (Promega) was carried out as per the manufacturer's protocol.
Statistical Analysis
Clinicopathological differences between patients with PD-L1-positive and PD-L1-negative tumors were compared by the chi-square test. Overall survival (OS) figures counted from the date of surgery were determined by the Kaplan-Meier method and compared with the log-rank test. Multivariate analysis was performed using a Cox proportional hazards regression model incorporating age, sex, histological subtype, and PD-L1 expression. MicroRNA expression levels of PD-L1-positive and PD-L1-negative patients were compared by using the Mann-Whitney U Test, as were differences in mRNA and microRNA expression in cell lines. A p value of 0.05 or less was considered statistically significant. IBM SPSS Statistics version 21 (IBM Corp., Armonk, NY) was used for statistical analyses.
Results
PD-L1 Expression Is a Marker of Poor Prognosis in MPM
We analyzed surgical samples from a series of 72 patients, including 35 with the epithelioid (48.6%), 25 with the biphasic (34.7%), and 12 with the sarcomatoid (16.7%) histological subtype. The median OS of 7.7 months (95% confidence interval: 5.6-9.8) in this series was lower than in some other reports, probably because this study included patients from 1992 to 2007, a period during which effective chemotherapy was not available (either because it was before publication of the pivotal cisplatin/pemetrexed data [2003] or because there was no reimbursement for pemetrexed in Australia [2003 to 2007] ), and thus, most patients did not receive any chemotherapy. In addition, the cohort had a higher than average proportion of patients with nonepithelioid tumors. PD-L1 expression was assessed in the TMAs, and examples of 10% and 90% positivity for PD-L1 expression are illustrated in Fig. 1A and B. Eighteen cases exhibited 5% or more PD-L1 membranous staining (25%). The median expression in PD-L1-positive cases was 29%, with a range from 5% to 100%. Five cases (7%) had 50% or higher expression. Patient characteristics ranked according to PD-L1 expression are shown in Table 1 . PD-L1 expression was more common in the nonepithelioid subtype than in the epithelioid subtype (p ¼ 0.01), and PD-L1 positivity was associated with poor survival (median OS ¼ 4.0 versus 9.2 months; p < 0.001 [ Fig. 1C]) . When adjusted for sex, age, and histological subtype in the Cox regression model, PD-L1 expression remained a significant adverse prognostic indicator (HR ¼ 2.2, 95% confidence interval: 1.2-4.1, p < 0.01) ( Table 2) .
Increased PD-L1 Expression Is Associated with Reduced MicroRNA Levels
To investigate whether PD-L1 expression in MPM was associated with microRNA expression, we used RT-qPCR to measure the expression of microRNAs predicted to target PD-L1 mRNA. A number of microRNAs are predicted to target either conserved or poorly conserved sites in the 3 0 UTR of PD-L1; they include the following: miR-155; members of the miR-15/16, miR-34, and miR-200 families; and the miR-17w92 cluster ( Fig. 2A  44 ) . The median microRNA expression levels of all members of the miR-15/16 family were lower in PD-L1-positive samples (n ¼ 13) than in PD-L1-negative (n ¼ 50) samples (significant in three of the four microRNAs of this family [ Fig. 2B] ). This was also the case for miR-200c, with a second member of the miR-200 family (miR-200b) showing a trend toward differential expression between the two groups without reaching statistical significance (see Fig. 2B ). In addition, median expression of the tumor suppressor microRNA miR-193a-3p expression was significantly lower in PD-L1-positive tumors (see Fig. 2B , p ¼ 0.039). The other microRNAs analyzed, including the three members of the miR-34 family, were not differentially expressed in PD-L1-positive and PD-L1-negative tumors (Fig. 2C ).
IRF1 Plays a Role in IFN-g-Induced PD-L1 Expression in MPM Cell Lines
Before investigating whether microRNAs contributed to regulation of PD-L1 expression, we first measured basal levels of PD-L1 in three MPM cell lines: H28, MSTO, and VMC23. H28 cells had the lowest expression, with ninefold and 14-fold greater levels in VMC23 and MSTO, respectively (Fig. 3A) . A previous study implicated IRF1 in both the constitutive and IFN-induced transcription of PD-L1 in lung cancer cells. 18 As IRF1 expression is stimulated by exposure of MPM cell lines to IFN-g 25 and the IRF1 mRNA also has target sites for tumor suppressor microRNAs that are down-regulated in MPM, we investigated the potential role of this transcription factor in the basal and IFN-g-induced expression of PD-L1. Basal expression of IRF1 showed a pattern similar to that of PD-L1, with higher expression in MSTO and VMC23 cells than in H28 cells (Fig. 3A) . MPM cells were transfected with two independent IRF1-specific siRNAs, with or without IFN-g stimulation, and the expression of IRF1 and PD-L1 mRNA was measured by RT-qPCR. Both siRNAs were very effective in silencing IRF1 in all three MPM cell lines, with silencing of 75% to 90% compared with controls, but this did not lead to a change in PD-L1 mRNA expression (Fig. 3B) . Upon IFN-g stimulation (10 ng/mL), both IRF1 and PD-L1 were significantly up-regulated in MPM cell lines (Fig. 3C) , and transfection with IRF1 siRNAs was able to reduce mRNA expression from both genes (Fig. 3D) . These data suggest that IRF1 contributes to the IFN-g-induced, but not basal, transcription of PD-L1 in these cells.
MicroRNAs Directly Regulate PD-L1 Expression in MPM
We previously showed that expression of the miR-15 family of microRNAs is significantly reduced in MPM cell lines compared with in the immortalized mesothelial cell line MeT-5A. 37 Although we did not observe a significant inverse correlation between levels of microRNAs and PD-L1 expression in the three cell lines studied, this was most likely due to low basal expression of the PD-L1 transcript in the H28 cells. To determine whether microRNAs could directly regulate PD-L1 expression, MPM cell lines (MSTO, H28, and VMC23) were transfected with microRNA mimics corresponding to miR-15a, miR-15b, and miR-16, which have a target site in the PD-L1 3 0 UTR (Fig. 4A ). After transfection with miR-15a, miR-15b, or miR-16 mimic, levels of PD-L1 mRNA were reduced in MSTO cells and to a lesser extent in VMC23 cells, but they were unchanged in H28 cells (Fig. 4B) . In complementary experiments, inhibition of miR-16 or miR-15b with specific inhibitors led to a slight increase in PD-L1 expression in MPM cell lines and, in the case of miR-16, a more pronounced increase in the immortalized mesothelial cell line MeT-5A (Supplementary Fig. 1 ). Regulation at the protein level was more dramatic, as seen in the immunohistochemical analysis of cell pellets (Fig. 4C) , with PD-L1 reduced to background levels in MSTO and VMC23 cells after transfection with miR-15a or miR-16 mimic. Staining in H28 cells was very low, which is consistent with the lower mRNA expression in this line (see Fig. 3A ). These results were confirmed by Western immunoblotting (see Fig. 4C) , showing substantial reductions in PD-L1 protein levels in MSTO and VMC23 cells.
To demonstrate direct interaction between microRNA mimics and the PD-L1 mRNA, we applied two methods. First, we measured the enrichment of PD-L1 mRNA in the fraction immunoprecipitated by AGO2 antibodies in total RNA from mimic-transfected MSTO cells. PCR analysis revealed a strong band in samples from miR15a-and miR-16-transfected cells that was absent in RNA from control mimic-transfected cells (Fig. 4D) . Second, we constructed a luciferase reporter by cloning a fragment of the PD-L1 3 0 UTR downstream of the Renilla luciferase gene. Results from dual luciferase assays demonstrated that miR-15a, miR-15b, miR-16, or miR193a-3p mimics all caused a reduction in luciferase activity in the MPM cell lines (Fig. 4E) .
In our AGO2 immunoprecipitation and luciferase experiments we also observed evidence of an interaction between the PD-L1 3 0 UTR and the miR-193a-3p mimic, which we had included as a second negative control (see Fig. 4D and E). This was somewhat unexpected, as although miR-193a-3p was lower in PD-L1-expressing tumor samples (see Fig. 2B ) standard prediction tools do not identify a target site for miR-193a-3p in the PD-L1 3 0 UTR. However, further investigation revealed an 8mer binding site containing a single GU wobble (Fig. 4F) , and transfection of MPM cells with miR-193a-3p led to a reduction in PD-L1 mRNA expression in VMC23 cells (Fig. 4G ) that was similar in magnitude to that induced by miR-15a, miR-15b, and miR-16, and to a lesser extent in MSTO cells. Somewhat unexpectedly, the low levels of PD-L1 mRNA in H28 cells were further reduced by miR-193a-3p transfection (see Fig. 4G ). In addition to the effects on PD-L1 mRNA, miR-193a-3p also reduced PD-L1 protein expression (Fig. 4H ), but only in VMC23 cells.
Discussion
Harnessing the immune checkpoint pathways as a therapeutic strategy, particularly using monoclonal antibodies against PD-1 or PD-L1, has recently been examined in trials in patients with melanoma, lung cancer, and other tumor types. 13, 14 The Keynote-028 phase I study demonstrated promising response and disease control rates in a small number of patients with MPM, 15 prompting widespread interest in using checkpoint inhibitors in MPM. Furthermore, the use of PD-L1 expression on tumor cells as a predictive biomarker is currently the subject of intense research. So far, little is known about the clinicopathological characteristics associated with PD-L1 expression in MPM. Here we have demonstrated that positive membranous PD-L1 staining was present in 25% of a series of patients with MPM who underwent pleurectomy with or without decortication surgery with mature follow-up data. This is comparable to the findings of a recently published study reporting PD-L1 positivity of 20.7%, 29 but it is considerably lower than the 40% reported in another study. 34 However, when only membranous staining is taken into account, all three studies reveal a similar PD-L1 positivity of slightly more than 20%. As in previous studies, our results also clearly show that PD-L1 expression is significantly more common in the nonepithelioid histological subtype of MPM and adversely associated with patient survival when adjusted for other known prognostic factors in a multivariate model. 34, 45 Although the PD-1/PD-L1 axis has been recognized as therapeutic target in MPM, the mechanisms responsible for upregulation of PD-L1 in MPM have not been investigated previously. Although studies have linked oncogenic mutations in ALK and EGFR to increased PD-L1 expression in lung cancer, 22 ,23 such mutations are rare in MPM. 46, 47 In the present study, we focused on microRNAs predicted to target PD-L1 or related pathways. We observed an inverse correlation between PD-L1 expression and expression of the miR-15/16 family in MPM tumor samples, which are microRNAs that we have previously shown to have tumor suppressor activity in MPM, 37 and we found that these microRNAs interact directly with the PD-L1 mRNA in vitro. Similarly, we found lower levels of two miR-200 family members in PD-L1-positive tumors. This mirrors the situation in lung cancer in which zinc finger E-box binding homeobox 1 (ZEB1) repression of miR-200 leads to increased PD-L1 expression and is associated with epithelialmesenchymal transition. 27 In addition, ZEB1 expression was shown to be higher in sarcomatoid MPM, which is the subtype with mesenchymal features, more frequent PD-L1 positivity, and worse prognosis. 48 Furthermore, in breast cancer cells, ZEB1 also suppresses miR-15/16 expression, 49 and hypoxia-induced dicer 1, ribonuclease III suppression reduces miR-200 processing, releasing the feedback inhibition of miR-200 on ZEB1 and eventually leading to EMT and the appearance of stem cell phenotypes. 50 In relation to immune therapybased cancer treatments, it is interesting to note that the ability of miR-16 to induce M1 macrophage differentiation and consequent T-cell activation in mice was shown to result in part from PD-L1 mRNA downregulation. 51 In contrast to recent findings in lung cancer, 28 we did not observe a relationship between the levels of mIR-34 family members and PD-L1 expression. This is possibly explained by the strong link between levels of miR-34 in lung cancer and p53 mutation, which is not a common feature of MPM. 52 Although miR-34b/c expression is silenced via promoter methylation in MPM, 53 the absolute levels of both miR-34b and miR-34c are lower than those of miR-34a, suggesting redundancy. A further feature distinguishing MPM from lung cancer is the lack of involvement of IRF1 in regulation of basal PD-L1 expression. We investigated IRF1 because it also contains target sites for many of the down-regulated microRNAs predicted to target PD-L1. It remains to be seen whether other transcription factors upregulated in lung cancer and linked with PD-L1 expression, such as nuclear factor kB 19 and IRF7 54 contribute to PD-L1 transcription in MPM. It is also notable that in the three cell lines tested, levels of PD-L1 mRNA and protein were not closely correlated; basal mRNA expression was similar in MSTO and VMC23 cells, whereas protein levels were much higher in the VMC23 cells. This suggests that in addition to the microRNAs investigated here, other posttranscriptional and/or posttranslation mechanisms contribute to regulation of PD-L1 protein expression in MPM.
We found an association between tumor PD-L1 positivity and reduced levels of miR-193a-3p, a microRNA we previously showed to be down-regulated and have tumor suppressor activity in MPM. 40 Although Targetscan and other algorithms do not predict an interaction between this microRNA and the PD-L1 3 0 UTR, it was also able to reduce PD-L1 protein expression in one of three MPM cell lines. Relaxing the stringency of the search to allow for GU wobble within the seed sequence revealed a noncanonical 8mer binding site, which may explain this unexpected finding. Although GU wobble and other noncanonical microRNA binding typically reduce microRNA activity, 55 there is biological evidence for many examples of nonconserved microRNA-mRNA interactions. 56 Interestingly, there is evidence for additional noncanonical microRNA binding sites in PD-L1: all three members of the miR-34 family were shown to suppress PD-L1 expression in lung cancer, 28 even though the seed in miR-34b is offset when compared with that in miR-34a and miR-34c. Further evidence linking miR-193a-3p to changes in PD-L1 expression may be relevant in MPM. In acute myeloid leukemia, the runt related transcription factor 1 (RUNX)/runt related transcription factor 1 translocation factor 1. Fusion protein reduces expression of the MIR193A promoter. 57 This leads to increases in a variety of miR-193a target genes (DNA methyltransferase 1 gene [DNMT] and histone deacetylases, class 1 [HDAC]), which in turn cause epigenetic silencing of phosphatase and tensin homolog expression; phosphatase and tensin homolog is inversely correlated with PD-L1 expression in SCLC 58 and is frequently down-regulated and linked to poor prognosis in MPM. 59 In conclusion, we have confirmed that the expression of PD-L1 is more common in nonepithelioid MPM and is associated with poor prognosis. PD-L1 expression in MPM is associated with changes in the expression of multiple tumor suppressor microRNAs, and these microRNAs can attenuate PD-L1 levels in vitro. Together, these data suggest that, at least in some cases, regulation of PD-L1 expression could contribute to the tumor suppressor effects of microRNAs frequently down-regulated in MPM. In this respect it will be interesting to see whether there is a link between PD-L1 expression and response in patients being treated with the microRNAbased therapy TargomiRs, which are currently nearing the end of phase I testing but already demonstrating signs of efficacy. 60 
